PExA operates in the medical technology sector and develops methods for collecting biomarkers. The company provides collection and measurement instruments, consumables and analysis services for examining patients' lungs. The products are primarily used in the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). In addition to its main business, service and technical support are offered. PExA was founded in 2014 and is headquartered in Gothenburg.
CEO
Chairperson of the Board
Board
| Name | Capital % | Votes % | Date |
|---|---|---|---|
| Nordnet Pensionsförsäkring | 19,33 | 18,74 | 2025-09-26 |
| Avanza Pension | 10,17 | 9,86 | 2025-09-26 |
| Daniel Nilsson privat och genom närstående | 8,58 | 8,32 | 2025-09-23 |
| Sven Christer Andersson | 8,21 | 7,96 | 2025-09-26 |
| Ola Hermansson | 5,11 | 5,14 | 2025-09-26 |
| Per Berger | 2,42 | 2,34 | 2025-09-26 |
| Anna-Carin Olin | 1,82 | 4,07 | 2025-09-26 |
| Mikael Blihagen | 1,74 | 1,69 | 2025-09-26 |
| Patrick Svensson | 1,17 | 1,13 | 2025-09-26 |
| Jörgen Östling | 1,15 | 1,11 | 2025-09-26 |
2025-11-07 Delårsrapport 2025-Q3
2026-02-19 Bokslutskommuniké 2025
